![]() |
JOURNAL TOOLS |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Per citare questo articolo |

I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS
Journal of Neurosurgical Sciences 2015 March;59(1):73-8
Copyright © 2015 EDIZIONI MINERVA MEDICA
lingua: Inglese
Hemicraniectomy for malignant middle cerebral artery territory infarction: an updated review
Taylor B. 1, 2, 3, Lopresti M. 2, Appelboom G. 1, 2, Sander Connolly E. Jr. 1, 2, 4 ✉
1 Department of Neurosurgery, Columbia University Medical Center, New York, NY, USA; 2 Cerebrovascular Lab, Columbia University Medical Center, New York, NY, USA; 3 College of Physicians and Surgeons, Columbia University, New York, NY, USA; 4 Neurocritical Care, Columbia University Medical Center, New York, NY, USA
A decompressive hemicraniectomy is frequently performed for patients with malignant middle cerebral artery territory infarction (MMI) to reduce the intracranial hypertension, which may otherwise result in transtentorial herniation. However, certain clinically significant issues ‑ diagnostic criteria, predictors of the MMI clinical course, benefit of surgery in certain populations, timing of surgery ‑ are unresolved. In this article, we provide an updated review on the diagnosis and management of MMI. An extensive search of the PubMed, EMBASE, and Cochrane was conducted using varying combinations of the search terms, “hemicraniectomy,” “decompressive craniectomy,” “malignant middle cerebral artery territory infarction,” “massive middle cerebral artery territory infarction,” “massive ischemic stroke,” “decompressive surgery,” and “neurosurgery for ischemic stroke.” Several large, randomized trials within the past decade have firmly established the benefit of decompressive hemicraniectomy (DHC) as a treatment of MMI. Further studies since then have not only better characterized the diagnosis and predictors of MMI, but have also shown that this benefit extends to patients with additional clinical and demographic characteristics. Future randomized studies should continue to evaluate the benefit of a DHC in other subgroups, and assess neurocognitive and psychosocial secondary outcomes.